Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Amortization of Deferred Charges (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 8 years of Amortization of Deferred Charges data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 3727.12% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.6 million, up 580.64%, while the annual FY2025 figure was $2.6 million, 580.64% up from the prior year.
  • Amortization of Deferred Charges reached $2.3 million in Q4 2025 per VRDN's latest filing, up from $102000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.3 million in Q4 2025 and bottomed at $49000.0 in Q3 2022.
  • Average Amortization of Deferred Charges over 5 years is $223437.5, with a median of $94500.0 recorded in 2021.
  • Peak YoY movement for Amortization of Deferred Charges: plummeted 52.03% in 2024, then surged 3727.12% in 2025.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $87000.0 in 2021, then surged by 47.13% to $128000.0 in 2022, then fell by 3.91% to $123000.0 in 2023, then crashed by 52.03% to $59000.0 in 2024, then soared by 3727.12% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $2.3 million in Q4 2025, $102000.0 in Q3 2025, and $103000.0 in Q2 2025.